Nawazish Khan
Medical Oncology · Cerritos, CANPI 1477753903
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $436,795 of the $439,156 with a category attached, or 99.5%. 26 manufacturers reported payments, led by Servier Pharmaceuticals LLC at 56.9% of the total. Reporting peaked in 2022 at $293,862 and has fallen 99.7% since, to $865 in 2025. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $6273.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$250K
- Servier Bioinnovation$184K
- AstraZeneca$3K
- Sanofi$417
- Karyopharm Therapeutics Inc.$247
- Incyte Corporation$231
- plus $1K from 20 others
Across 11 payments — averaging $9473.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$55K
- AbbVie$25K
- Coherus Oncology, Inc.$24K
What the payments were for
- Consulting fees$436,79599%
- Food & beverage$2,3131%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 9 | $249,775 |
| Servier Bioinnovation | 7 | $184,245 |
| AstraZeneca(2 entities) | 8 | $3,037 |
| Sanofi | 5 | $417 |
| Karyopharm Therapeutics Inc. | 2 | $247 |
| Incyte Corporation | 5 | $231 |
| AbbVie | 2 | $156 |
| Regeneron Healthcare Solutions, Inc. | 2 | $143 |
| Syndax Pharmaceuticals, Inc. | 1 | $137 |
| EMD Serono, Inc. | 1 | $118 |
| Bristol Myers Squibb | 3 | $89 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| Merck | 3 | $70 |
| Genentech USA, Inc. | 1 | $65 |
| Pfizer | 3 | $60 |
| Novartis | 2 | $45 |
| Amgen | 2 | $42 |
| Gilead(2 entities) | 2 | $34 |
| Pharmaessentia USA Corporation | 1 | $32 |
| Blueprint Medicines Corporation | 1 | $26 |
| Puma Biotechnology, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Seagen Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$439,156 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.
Other medical oncology in Cerritos
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.